Journal article
Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
Abstract
To the Editor: In the AMPLITUDE-O trial, Gerstein et al. (Sept. 2 issue)1 found a lower risk of cardiovascular events among participants with type 2 diabetes who received a weekly injection of efpe...
Authors
Borderie G; Schnebelen M; Baynat L
Journal
The New England Journal of Medicine, Vol. 385, No. 22, pp. 2105–2107
Publisher
Massachusetts Medical Society
Publication Date
November 25, 2021
DOI
10.1056/nejmc2115776
ISSN
0028-4793